Icu Medical Stock Intrinsic Value – ICU MEDICAL Reports 7.5% Decrease in Revenue for Q3 FY2023 with USD 553.3 Million Earnings
November 25, 2023
🌥️Earnings Overview
ICU MEDICAL ($NASDAQ:ICUI) reported total revenue of USD 553.3 million for the third quarter of FY2023, which was a 7.5% decrease from the same period in the previous year. Net income for the same period was USD 7.2 million, a 154.8% increase from the corresponding quarter of the prior year. This information was announced on September 30 2023.
Analysis – Icu Medical Stock Intrinsic Value
GoodWhale has conducted an analysis of ICU MEDICAL‘s wellbeing, and have come to a conclusion that the fair value of ICU MEDICAL share is around $237.9. This calculation was made through GoodWhale’s proprietary Valuation Line, which takes into account various factors like its financial health, market environment, and current stock performance. At the moment, ICU MEDICAL stock is traded at $102.0, which is significantly undervalued by 57.1%. This presents an opportunity for investors to take advantage of the current market situation and get a great return on investment. More…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Icu Medical. More…
| Total Revenues | Net Income | Net Margin |
| 2.25k | -28.04 | -0.1% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Icu Medical. More…
| Operations | Investing | Financing |
| 73.22 | -81.3 | -38.52 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Icu Medical. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 4.38k | 2.28k | 86.92 |
Key Ratios Snapshot
Some of the financial key ratios for Icu Medical are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 21.1% | -21.9% | 1.5% |
| FCF Margin | ROE | ROA |
| -0.6% | 1.0% | 0.5% |
Peers
It operates in a highly competitive market that includes major competitors such as Ypsomed Holding AG, Coloplast A/S, and Cardiovascular Systems Inc. These companies all strive to provide the best quality products and services to meet the needs of their customers.
– Ypsomed Holding AG ($LTS:0QLQ)
Ypsomed Holding AG is a leading Swiss medical technology company that designs, develops, and manufactures healthcare products for delivery of drugs and other treatments. The company has a market capitalization of 2.34 billion as of 2022, reflecting the confidence of investors in the company’s potential and its ability to grow in the coming years. Ypsomed Holding AG also has a Return on Equity of 4.93%, which is a measure of the company’s profitability relative to its shareholders’ equity. This indicates that the company is using its resources efficiently and delivering value to its shareholders.
– Coloplast A/S ($LTS:0QBO)
Coloplast A/S is a Danish medical device company that develops, manufactures, and markets medical products and services worldwide. The company has a market cap of 183.14B as of 2022 and a Return on Equity (ROE) of 50.58%. The market cap is an indication of the overall size of the company and its potential to generate profits. A high ROE indicates that the company is able to generate a significant return on the invested capital, making it an attractive investment. Coloplast is known for its products and services in the areas of urology, continence care, ostomy care, and wound and skin care, which have helped to ensure the company’s continued success.
– Cardiovascular Systems Inc ($NASDAQ:CSII)
Cardiovascular Systems Inc is a medical device company that develops, manufactures, and markets innovative interventional treatment systems for peripheral and coronary artery disease. The company has a market cap of 576.3M as of 2022 and a Return on Equity of -9.45%. This indicates that the company is not generating enough profits to cover its costs, which is not a good sign for the investors. Despite this, the company continues to innovate and develop new products in order to improve its financial performance.
Summary
Investors in ICU MEDICAL have reason to be optimistic, as the company reported strong financial results for the third quarter of FY2023. Total revenue for the quarter was USD 553.3 million, a 7.5% decrease from the previous year; however, net income skyrocketed by 154.8%, providing a total of USD 7.2 million for the quarter. This strong performance indicates that ICU MEDICAL is making sound financial decisions and is well-positioned for future growth. With the company’s solid financials and prospects for future success, investing in ICU MEDICAL is an attractive option.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
